시장보고서

상품코드

1463778

세계의 Drug Discovery 서비스 시장 : 시장 규모 및 점유율 분석 - 프로세스별, 종류별, 의약품 유형별, 치료 영역별, 최종사용자별 - 산업 수요 예측(-2030년)

Drug Discovery Services Market Size and Share Analysis by Process, Type, Drug Type, Therapeutic Area, End User - Global Industry Demand Forecast to 2030

발행일: 2024년 03월 | 리서치사:

Prescient & Strategic Intelligence | 페이지 정보: 영문 290 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시장 개요

세계의 Drug Discovery 서비스 시장 규모는 2023년에 210억 달러로 추산되며, 2030년에는 542억 달러에 달할 것으로 예측되고 있습니다. 또한 2024-2030년 CAGR은 14.7%에 상당합니다.

바이오의약품 업계 및 제약 업계에서 연구개발 투자의 증가, 분석 시험 시설의 아웃소싱 요구의 증가, 희소 의약품 및 희귀질환 연구 스텝, 자사에서의 의약품 개발에는 비용이 드는 것 등이 세계의 업계에서 새로운 매출의 문을 열고 있습니다.

주요 인사이트

2023년, Drug Discovery 서비스 업계에서는 히트·투·리드 식별 카테고리가 35%의 최대 점유율을 차지했습니다.

2023년에는 화학 카테고리가 시장에서 60%의 최고 점유율을 차지하고 있습니다.

저분자 의약품 카테고리는 업계에서 큰 점유율을 차지하고 있으며, 세계의 신규 치료법의 출현에 필수적입니다. 저분자 의약품은 특수 의약품 판매의 50%를 차지하며 2020년 FDA 승인의 75% 이상을 차지하고 있습니다.

북미 지역은 최근 의약품 개발 서비스에서 55%라는 최대 업계 점유율을 차지하고 있습니다.

세계의 Drug Discovery 서비스 시장을 분석했으며, 시장의 기본 구조·최신 상황 및 주요 촉진·억제요인, 세계 전체 및 지역별·주요 국가 시장 규모의 동향 전망(금액 기반, 2017-2030년), 프로세스별·종류별·의약품 유형별·치료 영역별·최종사용자별의 상세 동향, 현재의 시장 경쟁 상황, 주요 기업의 개요 등을 조사하여 전해드립니다.

The growing research and development investments of the biopharmaceutical and pharmaceutical industries, the increasing need for outsourcing analytical testing facilities, steps for orphan drug and rare illness research, and the costly nature of the in-house drug expansion procedure are all opening up new revenue gates in the worldwide industry.

One of the reasons for the escalating demand for outsourcing clinical testing and analytical research services for biopharmaceutical drugs is the rising expenditure of R&D activities that are majorly channelled toward orphan drugs that are meant to suppress rare conditions.

On the other hand, the biopharmaceutical industry has been growing exceptionally due to the ever-increasing demands for biologics and the invention of and manufacturing of several innovative and life-saving drugs. Moreover, the bioscience industry profits from the investment in research of the new covered drugs for common and rare diseases. The market of drug discovery is also solving the problem of patents' expiration as well as the growing need for biologics in emerging economies.

Key Insights

In 2023, the hit-to-lead identification category held the largest share of 35% in the drug discovery services industry.

This procedure is vital in initial drug research and includes outsourcing to attain economies of scale and effectiveness for medicinal businesses.

Pioneering in-silico methods such as computer-aided drug discovery and structure-based medication designs contribute to the development of this category.

High-throughput screening plays a major role in hit-to-lead identification, eased by improvements in robotics, liquid management, plate reader discovery, and computing power.

Because of the dedicated and expensive nature of HTS, several organizations, particularly those with limited backing, select to outsource such services to Contract Research Organizations for high-quality and lucrative solutions.

In 2023, the chemistry category grips a leading share of 60% in the market.

Besides drug discovery, medicinal chemistry provides action at every stage, starting from pre-clinical evaluation to the delivery of a drug candidate.

The medical chemistry market is growing as companies work to find new ways to outsource tasks such as R&D services.

Such growth is continuously fostered by an increase in the number of overhead costs incurred during the pharmaceutical discovery and development processes.

Small-molecule drugs category grips a substantial industry share and is vital in emerging novel treatments worldwide.

Small-molecule drugs account for 50% of specialty drug sales and comprised over 75% of all FDA approvals in 2020.

They play a critical role in treating cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.

The North American region holds the largest industry share of 55% in the recent years in drug advancement services.

The region aids from several Contract Research Organizations and Contract Manufacturing Organizations backing key pharmaceutical and biopharmaceutical firms, contributing to industry growth.

Numerous newly developed drugs have their patents held in the U.S., additionally boosting the industry.

Reasons propelling industry development include an increasing elderly populace, growing occurrence of chronic illnesses, technical improvements in biotechnology and pharmaceutical industries, recognized reimbursement guidelines, advanced medicinal infrastructure, rising awareness of initial disease diagnosis, and the reequipment for better patient care.

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by process
- 1.4.2. Market size breakdown, by type
- 1.4.3. Market size breakdown, by drug type
- 1.4.4. Market size breakdown, by therapeutic area
- 1.4.5. Market size breakdown, by end user
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Process (2017-2030)
6.3. Market Revenue, by Type (2017-2030)
6.4. Market Revenue, by Drug Type (2017-2030)
6.5. Market Revenue, by Therapeutic Area (2017-2030)
6.6. Market Revenue, by End User (2017-2030)
6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Process (2017-2030)
7.3. Market Revenue, by Type (2017-2030)
7.4. Market Revenue, by Drug Type (2017-2030)
7.5. Market Revenue, by Therapeutic Area (2017-2030)
7.6. Market Revenue, by End User (2017-2030)
7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Process (2017-2030)
8.3. Market Revenue, by Type (2017-2030)
8.4. Market Revenue, by Drug Type (2017-2030)
8.5. Market Revenue, by Therapeutic Area (2017-2030)
8.6. Market Revenue, by End User (2017-2030)
8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Process (2017-2030)
9.3. Market Revenue, by Type (2017-2030)
9.4. Market Revenue, by Drug Type (2017-2030)
9.5. Market Revenue, by Therapeutic Area (2017-2030)
9.6. Market Revenue, by End User (2017-2030)
9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Process (2017-2030)
10.3. Market Revenue, by Type (2017-2030)
10.4. Market Revenue, by Drug Type (2017-2030)
10.5. Market Revenue, by Therapeutic Area (2017-2030)
10.6. Market Revenue, by End User (2017-2030)
10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Process (2017-2030)
11.3. Market Revenue, by Type (2017-2030)
11.4. Market Revenue, by Drug Type (2017-2030)
11.5. Market Revenue, by Therapeutic Area (2017-2030)
11.6. Market Revenue, by End User (2017-2030)
11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Process (2017-2030)
12.3. Market Revenue, by Type (2017-2030)
12.4. Market Revenue, by Drug Type (2017-2030)
12.5. Market Revenue, by Therapeutic Area (2017-2030)
12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Process (2017-2030)
13.3. Market Revenue, by Type (2017-2030)
13.4. Market Revenue, by Drug Type (2017-2030)
13.5. Market Revenue, by Therapeutic Area (2017-2030)
13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Process (2017-2030)
14.3. Market Revenue, by Type (2017-2030)
14.4. Market Revenue, by Drug Type (2017-2030)
14.5. Market Revenue, by Therapeutic Area (2017-2030)
14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Process (2017-2030)
15.3. Market Revenue, by Type (2017-2030)
15.4. Market Revenue, by Drug Type (2017-2030)
15.5. Market Revenue, by Therapeutic Area (2017-2030)
15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Process (2017-2030)
16.3. Market Revenue, by Type (2017-2030)
16.4. Market Revenue, by Drug Type (2017-2030)
16.5. Market Revenue, by Therapeutic Area (2017-2030)
16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Process (2017-2030)
17.3. Market Revenue, by Type (2017-2030)
17.4. Market Revenue, by Drug Type (2017-2030)
17.5. Market Revenue, by Therapeutic Area (2017-2030)
17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Process (2017-2030)
18.3. Market Revenue, by Type (2017-2030)
18.4. Market Revenue, by Drug Type (2017-2030)
18.5. Market Revenue, by Therapeutic Area (2017-2030)
18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Process (2017-2030)
19.3. Market Revenue, by Type (2017-2030)
19.4. Market Revenue, by Drug Type (2017-2030)
19.5. Market Revenue, by Therapeutic Area (2017-2030)
19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Process (2017-2030)
20.3. Market Revenue, by Type (2017-2030)
20.4. Market Revenue, by Drug Type (2017-2030)
20.5. Market Revenue, by Therapeutic Area (2017-2030)
20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Process (2017-2030)
21.3. Market Revenue, by Type (2017-2030)
21.4. Market Revenue, by Drug Type (2017-2030)
21.5. Market Revenue, by Therapeutic Area (2017-2030)
21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Process (2017-2030)
22.3. Market Revenue, by Type (2017-2030)
22.4. Market Revenue, by Drug Type (2017-2030)
22.5. Market Revenue, by Therapeutic Area (2017-2030)
22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Process (2017-2030)
23.3. Market Revenue, by Type (2017-2030)
23.4. Market Revenue, by Drug Type (2017-2030)
23.5. Market Revenue, by Therapeutic Area (2017-2030)
23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Process (2017-2030)
24.3. Market Revenue, by Type (2017-2030)
24.4. Market Revenue, by Drug Type (2017-2030)
24.5. Market Revenue, by Therapeutic Area (2017-2030)
24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Process (2017-2030)
25.3. Market Revenue, by Type (2017-2030)
25.4. Market Revenue, by Drug Type (2017-2030)
25.5. Market Revenue, by Therapeutic Area (2017-2030)
25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Process (2017-2030)
26.3. Market Revenue, by Type (2017-2030)
26.4. Market Revenue, by Drug Type (2017-2030)
26.5. Market Revenue, by Therapeutic Area (2017-2030)
26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Process (2017-2030)
27.3. Market Revenue, by Type (2017-2030)
27.4. Market Revenue, by Drug Type (2017-2030)
27.5. Market Revenue, by Therapeutic Area (2017-2030)
27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Process (2017-2030)
28.3. Market Revenue, by Type (2017-2030)
28.4. Market Revenue, by Drug Type (2017-2030)
28.5. Market Revenue, by Therapeutic Area (2017-2030)
28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Charles River Laboratories International Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Eurofins Scientific Limited
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Frontage Laboratories Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. Galapagos NV
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. General Electric
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Laboratory Corporation of America Holdings
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. Thermo Fisher Scientific Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Syngene International Limited
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. WuXi AppTec
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations
31.2. Sources and References
31.3. Related Reports

세계의 Drug Discovery 서비스 시장 : 시장 규모 및 점유율 분석 - 프로세스별, 종류별, 의약품 유형별, 치료 영역별, 최종사용자별 - 산업 수요 예측(-2030년)

Drug Discovery Services Market Size and Share Analysis by Process, Type, Drug Type, Therapeutic Area, End User - Global Industry Demand Forecast to 2030

목차

제1장 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 지표

제5장 업계의 전망

제6장 세계 시장

제7장 북미 시장

제8장 유럽 시장

제9장 아시아태평양 시장

제10장 라틴아메리카 시장

제11장 중동 및 아프리카 시장

제12장 미국 시장

제13장 캐나다 시장

제14장 독일 시장

제15장 프랑스 시장

제16장 영국 시장

제17장 이탈리아 시장

제18장 스페인 시장

제19장 일본 시장

제20장 중국 시장

제21장 인도 시장

제22장 호주 시장

제23장 한국 시장

제24장 브라질 시장

제25장 멕시코 시장

제26장 사우디아라비아 시장

제27장 남아프리카공화국 시장

제28장 아랍에미리트(UAE) 시장

제29장 경쟁 구도

제30장 기업 개요

제31장 부록

Table of Contents